



दि प्लास्टिक एक्सपोर्ट प्रमोशन कौन्सिल

(भारत सरकार, वाणिज्य एवं उद्योग मंत्रालय, वाणिज्य विभाग द्वारा प्रायोजित)
क्रिस्टल टावर, मुदिवली रोड क्र. 3, ऑफ सर एम व्ही रोड, अंधेरी (पूर्व), मुंबई ४०० ०६९, भारत
दूरध्वनी : ९१-२२-२६८३ ३९९१/९२ फैक्स : ९१-२२-२६८३ ३९९३
ई-मेल : plexconcil@vsnl.com वेबसाईट : http://www.plexconcil.org

THE PLASTICS EXPORT PROMOTION COUNCIL

(Sponsored by the Ministry of Commerce & Industry, Department of Commerce, Government of India)
Crystal Tower, Gundivali Road No 3, Off Sir M V Road, Andheri (E), Mumbai 400069 - India
Ph: (+91 - 22) 26833951, Fax: (+91 - 22) 26833953 / 26834057
Email: plexconcil@vsnl.com Website: http://www.plexconcil.org

Ref. : Plexh/cir/708

25.05.2018

To,

All Members / COA

Dear Sir/Madam,

Sub : Regarding Inter-Ministerial meeting on 28th May, 2018 for India-EU Sub Commission on Trade meeting scheduled to be held on 6th June, 2018 in New Delhi.

We are in receipt of communication from Department of Commerce, Government of India regarding Inter-Ministerial Meeting to be held on 28th May, 2018 at 3:00 PM in Udyog Bhawan, New Delhi for India-EU Sub Commission on Trade to be held on 6th June, 2018 in New Delhi.

We further would like to inform you that meeting of EU- India Sub- Commission on Trade was held on 12th July 2017 in Brussels (copy of minutes available at the web link <https://bit.ly/2kqq6N6> . **Members are requested to refer para 5.7 of attached minutes and give their inputs urgently (today).**

Details about para 5.7 given below for your reference:-

Point no. 5 - MARKET ACCESS ISSUES

Sub point 5.7 Medical Devices: Price Control in India (e.g. coronary stents)

The EU side raised concern with regard to India's recent decisions to include coronary stents in the National List of Essential Medicines and to extend the price monitoring scheme to a number of additional medical devices. The EU side conveyed that the industry lacks access to remedial mechanisms to challenge decisions affecting pricing and reimbursement taken by the Indian authorities and that current price caps no longer make India a viable market for EU companies. The Indian side said that its price control policy was legitimate and necessary to address unacceptably high prices of imported stents. The Indian side informed that there is no restriction for EU companies to provide innovative medical devices on the Indian market. The Indian side explained that its decisions are based on stakeholder's consultation, including industry, as well as a cost analysis.

The EU side sought clarification as regards the delay for withdrawal of products from the Indian market. The Indian side stated that the period for withdrawal of products from the India is six months.

The EU side proposed to start a technical dialogue on key approaches (e.g health technology assessment) regarding cost- containment of healthcare spending. The Indian side indicated the existing EU – India Joint Working Group on Pharmaceuticals, Biotechnology and Medical Devices as a forum for such technical dialogue.

Your early replies will be appreciated so as to enable us to represent to the ministry.

Best Regards,

Sribash Dasmohapatra
(Executive Director)